SCHEMBL17788741

SCHEMBL17788741

Cc1cc(-c2ncn(C=C(C(=O)N(C)C)c3ccncc3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
XPO1 O14980 9/20 0.52
RANBP1 P43487 1/20 0.52
KCNH2 Q12809 1/20 0.52
ESR1 P03372 1/20 0.42
HTR1A P08908 1/20 0.42
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
HRH1 P35367 1/20 0.42
PDE4D Q08499 1/20 0.42
SLC29A1 Q99808 1/20 0.42
GPBAR1 Q8TDU6 8/20 0.38
KLRK1 P26718 1/20 0.36
MICA Q29983 1/20 0.36
RAET1L Q5VY80 1/20 0.36
EGFR P00533 1/20 0.35
FGFR1 P11362 1/20 0.35
KDR P35968 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17788740 1.00 XPO1 (0.52) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788746 1.00 XPO1 (0.52) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17782105 0.94 XPO1 (0.59) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16361450 0.94 XPO1 (0.59) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL16361340 0.94 XPO1 (0.59) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788723 0.90 XPO1 (0.54) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788724 0.90 XPO1 (0.54) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788722 0.90 XPO1 (0.54) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788726 0.89 XPO1 (0.67) XPO1RANBP1KCNH2ESR1HTR1A
SCHEMBL17788728 0.89 XPO1 (0.67) XPO1RANBP1KCNH2ESR1HTR1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. 2018-06-07 US disclosed
US-9738624-B2 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. (US) 2017-08-22 US disclosed
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof Karyopharm Therapeutics Inc. (US) 2016-06-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180155317-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, XPO5, XPOT XPO1 1/4885RANBP1 159/4885KCNH2 4379/4885
US-20160152596-A1 Nuclear Transport Modulators and Uses Thereof XPO5, XPO1, XPOT XPO1 2/4885RANBP1 144/4885KCNH2 4320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.